Sino-US medical bridge: A shared frontier in cancer care

In the operation theater, the mission to save lives is a universal language that unites doctors across all borders. For over four decades, Professor Zhou Qinghua, director of the West China Lung Cancer Center and a globally recognized authority in oncology, has occupied a unique position at the intersection of Chinese clinical mastery and global collaboration, proving that in the fight against cancer, the most effective tool is a shared commitment to medical innovation.

The foundation of this medical bridge was laid in 1994 during Professor Zhou's tenure at Vanderbilt University in the US. This early immersion sparked a long-standing partnership with the US National Institutes of Health (NIH) and the National Cancer Institute (NCI). Serving as an expert on the NIH-NCI Lung Cancer Biomarker Group and the NIH-EDRN Lung Cancer Expert Group, Zhou evolved from a research participant into a key architect of global standards. 

At major international forums like the World Conference on Lung Cancer (WCLC), Zhou presented longitudinal data on high-difficulty surgeries involving tumors invading the heart or great vessels — cases traditionally deemed "inoperable" by Western medicine. 

While the international five-year survival rate for such late-stage cases averaged less than 10%, Zhou's team at West China Hospital achieved a groundbreaking rate of over 30%. These results directly influenced the revision of the International Association for the Study of Lung Cancer (IASLC) guidelines, ensuring Chinese clinical progress now informs the global gold standard of care.

The global impact of Professor Zhou's expertise is measured both in clinical trust and academic prestige. The past few months alone have seen four American patients travel to China specifically for his surgical intervention in complex, high-stakes cases. 

This clinical trust is matched by his commitment to professional exchange: from performing joint surgeries with Professor Ralph Schmid, president of the European Association for Cardio-Thoracic Surgery (EACTS), to welcoming specialists from the University of Toronto to study his techniques in artificial vascular replacement, Zhou continues to foster a spirit of shared learning and partnership within the global medical community. 

In an increasingly volatile world, medicine remains a vital common ground. When top-tier minds prioritize human health over friction, the result is a more robust, evidence-based future for patients everywhere. In the pursuit of saving lives, cooperation is the only viable path forward.